Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study

被引:23
作者
Johnson, Kyle [1 ]
Oparil, Suzanne [2 ]
Davis, Barry R. [3 ]
Tereshchenko, Larisa G. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA
[2] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA
[3] Univ Texas Sch Publ Hlth, Houston, TX USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2019年 / 8卷 / 08期
关键词
antihypertensive agent; ECG; heart failure; hypertension; left ventricular hypertrophy; OUTCOMES; CHLORTHALIDONE; ASSOCIATIONS; MECHANISMS; PREDICTOR;
D O I
10.1161/JAHA.119.011961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Hypertension is a known risk factor for heart failure (HF), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy (LVH). We studied the extent to which blood pressure (BP) change and evolving LVH contribute to the effect that lisinopril, doxazosin, and amlodipine have on HF compared with chlorthalidone. Methods and Results-We conducted causal mediation analysis of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) data (1994-2002; in-trial follow-up). ALLHAT participants with available serial ECGs and BP measurements were included (n=29 892; mean age 67 +/- 4 years; 32% black; 56% men): 11 008 were randomized to chlorthalidone, 5967 to doxazosin, 6593 to amlodipine, and 6324 to lisinopril. Evolving ECG LVH and BP lowering served as mediators. Incident symptomatic HF was the primary outcome. Linear regression (for mediator) and logistic regression (for outcome) models were adjusted for mediator-outcome confounders (demographic and clinical characteristics known to be associated both with both LVH/hypertension and HF). A large majority of participants (96%) had ECG LVH status unchanged, but 4% developed evolving ECG LVH. On average, BP decreased by 11/7 mm Hg. In adjusted Cox regression analyses, progressing ECG LVH (hazard ratio [HR] 1.78 [95% CI 1.43-2.22]), resolving ECG LVH (HR 1.33 [95% CI 1.03-1.70]), and baseline ECG LVH (1.17 [95% CI 1.04-1.31]) carried risk of incident HF. After full adjustment, evolving ECG LVH mediated 4% of the effect of doxazosin on HF. Systolic BP lowering mediated 12% of the effect of doxazosin, and diastolic BP lowering mediated 10% of the effect of doxazosin, 7% of the effect of amlodipine, and borderline 9% of the effect of lisinopril on HF. Conclusions-Evolving ECG LVH and BP change account for 4% to 13% of the mechanism by which antihypertensive medications prevent HF.
引用
收藏
页数:15
相关论文
共 29 条
[1]  
[Anonymous], 2010, MINNESOTA CODE MANUA, DOI DOI 10.1007/978-1-84882-778-3
[2]   Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review [J].
Bang, Casper N. ;
Devereux, Richard B. ;
Okin, Peter M. .
JOURNAL OF ELECTROCARDIOLOGY, 2014, 47 (05) :630-635
[3]   Global ECG Measures and Cardiac Structure and Function The ARIC Study (Atherosclerosis Risk in Communities) [J].
Biering-Sorensen, Tor ;
Kabir, Muammar ;
Waks, Jonathan W. ;
Thomas, Jason ;
Post, Wendy S. ;
Soliman, Elsayed Z. ;
Buxton, Alfred E. ;
Shah, Amil M. ;
Solomon, Scott D. ;
Tereshchenko, Larisa G. .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2018, 11 (03)
[4]   Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives [J].
Cacciapuoti, Federico .
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2011, 5 (06) :449-455
[5]   Prognostic associations of Minnesota code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial [J].
Crow, RS ;
Prineas, RJ ;
Hannan, PJ ;
Grandits, G ;
Blackburn, H .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (02) :138-144
[6]   Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [J].
Davis, Barry R. ;
Kostis, John B. ;
Simpson, Lara M. ;
Black, Henry R. ;
Cushman, William C. ;
Einhorn, Paula T. ;
Farber, Michael A. ;
Ford, Charles E. ;
Levy, Daniel ;
Massie, Barry M. ;
Nawaz, Shah .
CIRCULATION, 2008, 118 (22) :2259-2267
[7]   Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].
Davis, BR ;
Cutler, JA ;
Gordon, DJ ;
Furberg, CD ;
Wright, JT ;
Cushman, WC ;
Grimm, RH ;
LaRosa, J ;
Whelton, PK ;
Perry, HM ;
Alderman, MH ;
Ford, CE ;
Oparil, S ;
Francis, C ;
Proschan, M ;
Pressel, S ;
Black, HR ;
Hawkins, CM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360
[8]   Role of diuretics in the prevention of heart failure - The antihypertensive and lipid-lowering treatment to prevent heart attack trial [J].
Davis, BR ;
Piller, LB ;
Cutler, JA ;
Furberg, C ;
Dunn, K ;
Franklin, S ;
Goff, D ;
Leenen, F ;
Mohiuddin, S ;
Papademetriou, V ;
Proschan, M ;
Ellsworth, A ;
Golden, J ;
Colon, P .
CIRCULATION, 2006, 113 (18) :2201-2210
[9]   ALLHAT: Setting the record straight [J].
Davis, BR ;
Furberg, CD ;
Wright, JT ;
Cutler, JA ;
Whelton, P .
ANNALS OF INTERNAL MEDICINE, 2004, 141 (01) :39-46
[10]   The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) Heart Failure Validation Study: Diagnosis and prognosis [J].
Einhorn, Paula T. ;
Davis, Barry R. ;
Massie, Barry M. ;
Cushman, William C. ;
Piller, Linda B. ;
Simpson, Lara M. ;
Levy, Daniel ;
Nwachuku, Chuke E. ;
Black, Henry R. .
AMERICAN HEART JOURNAL, 2007, 153 (01) :42-+